Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
18/11/2025 12:26
Nov 18 (Reuters) - Esperion Therapeutics Inc ESPR.O: ESPERION PARTNER HLS THERAPEUTICS ANNOUNCES APPROVAL OF NILEMDO® FOR THE REDUCTION OF LDL-CHOLESTEROL IN CANADIANS AT RISK OF CARDIOVASCULAR DISEASE ESPERION THERAPEUTICS INC -COMMERCIAL LAUNCH FOR NILEMDO IS EXPECTED IN Q2 2026 Source text: nGNX8QqcJZ Further company coverage: ESPR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Esperion Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi